Zydus Wellness Ltd. News and Updates

Keep track of all breaking news on Zydus Wellness Ltd. from all sources in a single place.

Zydus Wellness Ltd.

16 Apr 2025

1762.70

-0.15%

Zydus, Lupin shares fall over US court ruling in Myrbetriq patent case

Business Standard

Companies say they are in process of assessing impact of order on operations

Zydus Wellness Ltd. is trading below its 100 day SMA of 1809.8

Zydus Wellness Ltd.

15 Apr 2025

1762.70

-0.15%

Zydus Lifesciences Share Price Spikes On Acquisition, New Drug Approval

NDTV Profit

The drugmaker has received the USFDA's final approval to manufacture a particular corticosteroid called Deflazacort to treat Duchenne muscular dystrophy.

Zydus Wellness Ltd. is trading above its 50 day SMA of 1680.5

Zydus Wellness Ltd.

01 Apr 2025

1762.70

-0.15%

US Tariffs on Pharma: Zydus, Dr Reddy's at highest risk, says Jefferies; Check impact on other Indian pharma stocks

livemint

US Tariffs on Pharma: Given Zydus Lifesciences and Dr Reddy's Laboratories have high US sales exposure with ~45% and 43% sales contribution, Jefferies believes they are at highest risk among generics.

Zydus Wellness Ltd. is trading above its 50 day SMA of 1680.5

Zydus Wellness Ltd.

28 Mar 2025

1762.70

-0.15%

Zydus Life extends timeline for Sterling Biotech API business acquisition

Business Standard

The company had first disclosed the deal on September 17, 2024, after signing a business transfer agreement (BTA) with SBL

Zydus Wellness Ltd. is trading below its 100 day SMA of 1809.8

Zydus Family Trust buys Rs 200 cr luxury flat in Worli's Oberoi 360 West

Business Standard | 28 Mar 2025

Zydus Wellness Ltd.

19 Mar 2025, 10:44AM

1762.70

-0.15%

Here's why Zydus Lifesciences share price popped 3% in trade on March 19

Business Standard

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg

Zydus Wellness Ltd. is trading above its 50 day SMA of 1680.5

Zydus Lifesciences Gets FDA Approval To Manufacture Apalutamide Tablets

NDTV Profit | 18 Mar 2025

Zydus Wellness Ltd.

17 Mar 2025

1762.70

-0.15%

Here's why Zydus Lifesciences share price was buzzing in trade on March 17

Business Standard

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg

Zydus Wellness Ltd. is trading below its 100 day SMA of 1809.8

Sun Pharma, Zydus recall medicines in US over quality concerns: USFDA

Business Standard | 16 Mar 2025

Zydus Wellness Ltd.

14 Mar 2025

1762.70

-0.15%

Expanding product portfolio to drive growth for Zydus Lifesciences

Business Standard

The near term trigger for the stock is its plan to acquire Amplitude Surgical

Zydus Wellness Ltd. is trading below its 100 day SMA of 1809.8

Zydus Wellness Ltd.

12 Mar 2025

1762.70

-0.15%

Zydus gains FDA approval for urinary tract infection medication

Business Line

The approval strengthens Zydus' position in the US pharmaceutical market, bringing the company's total to 419 USFDA approvals

Zydus Wellness Ltd. has an average target of 2054.00 from 2 brokers.

Zydus Life Gets USFDA Nod To Make Generic UTI Treatment Drug

NDTV Profit | 12 Mar 2025 4 more

Zydus Wellness Ltd.

11 Mar 2025

1762.70

-0.15%

Zydus Lifesciences to buy 85% stake in Amplitude Surgical for 256 mn euros

Business Standard

Zydus Lifesciences on Tuesday said it has entered into exclusive negotiations to acquire a majority stake in France-based Amplitude Surgical for 256.8 million euros. The company has entered into negotiations with PAI Partners, Amplitude Surgical's management, as well as two minority shareholders to acquire 85.6 per cent of the company's share capital, the Ahmedabad-based drug maker said in a regulatory filing. Purchase consideration amounts to 256.8 million euros for 85.6 per cent of the outstanding shares and voting rights of Amplitude Surgical, it added. Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. The company provides numerous value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. This includes the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of